Creating a human-made antivenom for snake bites
Development of World's First Fully Human Broad Spectrum Anti-Snake Venom
This study is working on a new type of snakebite treatment made from human antibodies that can safely and effectively fight off toxins from different snakes, so you won't need multiple antivenoms and can get treated more easily.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Centivax INC NIH-funded |
| Lab location | 1 site (South San Francisco, UNITED STATES) |
| Project ID | NIH-10908341 on NIH RePORTER |
What this research studies
This research focuses on developing a fully human broad-spectrum antivenom that can effectively treat snakebite envenoming. By utilizing human recombinant antibodies, the goal is to create a single product that can neutralize toxins from various snake species, eliminating the need for multiple animal-derived antivenoms. The approach aims to reduce adverse reactions associated with traditional antivenoms and allow for safer administration methods, such as intramuscular delivery. The research builds on previous findings that demonstrated the efficacy of these human antibodies in animal models.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who have been bitten by snakes and require antivenom treatment.
Not a fit: Patients who have not been exposed to snake venom or those with allergies to human-derived products may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a safer and more effective treatment for snakebite victims worldwide.
How similar studies have performed: Previous research has shown promise in using human antibodies for treating various conditions, indicating potential success for this novel approach.
Where this research is happening
South San Francisco, UNITED STATES
- Centivax INC — South San Francisco, United States (Active)
Researchers
- Principal investigator: Glanville, Jacob — Centivax INC
- Study coordinator: Glanville, Jacob
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.